Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiometabolic treatment with 90Y-DOTATOC or 90Y-DOTATATE in neuroendocrine tumors
2012-003155-11Phase 2Active
- Sponsor
- AUSL Cesena
- Start
- Aug 2012
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
A Phase 2 trial of yttrium-90 edotreotide, lutetium Lu 177 dotatate in apudoma (NET), endocrine neoplasm (NET), sponsored by AUSL Cesena. Started Aug 2012; status: active.
02
Drugs
yttrium-90 edotreotidelutetium Lu 177 dotatate
03
Conditions
apudoma (NET)endocrine neoplasm (NET)
Beyond the preview
Go deeper on 2012-003155-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003155-11.